Evidence map›Paper›PMID 33589556›Full record

ArticleThe Journal of rheumatology2021

Diagnostic Delay in Psoriatic Arthritis: A Population-based Study.

Paras Karmacharya, Kerry Wright, Sara J Achenbach, Delamo Bekele, Cynthia S Crowson, Alexis Ogdie, Alí Duarte-García, Floranne C Ernste, Megha M Tollefson, John M Davis

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Review
  13. Article
  14. [Advances of low-intensity pulsed ultrasound for treatment of musculoskeletal disorders in the past decade].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025
    Review
  15. Article
  16. Article
  17. Article
  18. Effect of Biological Therapy for Psoriasis on the Development of Psoriatic Arthritis: A Population-Based Cohort Study.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Paras KarmacharyaP. Karmacharya, MBBS, K. Wright, MBBS, D. Bekele, MBBS, F.C. Ernste, MD, J.M. Davis III, MD, MS, Division of Rheumatology, Mayo Clinic; paraskarmacharya@gmail.com.ORCID 0000-0003-1034-1530
Kerry WrightP. Karmacharya, MBBS, K. Wright, MBBS, D. Bekele, MBBS, F.C. Ernste, MD, J.M. Davis III, MD, MS, Division of Rheumatology, Mayo Clinic.
Sara J AchenbachS.J. Achenbach, MS, Department of Health Sciences Research, Mayo Clinic.
Delamo BekeleP. Karmacharya, MBBS, K. Wright, MBBS, D. Bekele, MBBS, F.C. Ernste, MD, J.M. Davis III, MD, MS, Division of Rheumatology, Mayo Clinic.
Cynthia S CrowsonC.S. Crowson, PhD, Division of Rheumatology, and Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0001-5847-7475
Alexis OgdieA. Ogdie, MD, MSCE, Departments of Medicine/Rheumatology and Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0002-4639-0775
Alí Duarte-GarcíaA. Duarte-García, MD, MSc, Division of Rheumatology, and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic.ORCID 0000-0003-1749-5719
Floranne C ErnsteP. Karmacharya, MBBS, K. Wright, MBBS, D. Bekele, MBBS, F.C. Ernste, MD, J.M. Davis III, MD, MS, Division of Rheumatology, Mayo Clinic.
Megha M TollefsonM.M. Tollefson, MD, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA.
John M DavisP. Karmacharya, MBBS, K. Wright, MBBS, D. Bekele, MBBS, F.C. Ernste, MD, J.M. Davis III, MD, MS, Division of Rheumatology, Mayo Clinic.ORCID 0000-0002-9710-8143
WinnMed · USMayo Clinic in Arizona · USMayo Clinic in Florida · USEstonian Business School · EEUniversity of Pennsylvania · US

Funding

Mayo Clinic Center for Clinical and Translational Science (CCaTS UL1 Supplement - Dr. Timothy Curry)UL1TR002377 · NCATS · MAYO CLINIC ROCHESTER · PI VESNA D GAROVIC · 2017 to 2026
$78.4M
Rochester Epidemiology ProjectR01AG034676 · NIA · MAYO CLINIC ROCHESTER · PI ROCCA, WALTER A, ST SAUVER, JENNIFER LYNN · 2010 to 2019
$9.5M
Musculoskeletal Research Training ProgramT32AR056950 · NIAMS · MAYO CLINIC ROCHESTER · PI Jennifer J Westendorf · 2009 to 2026
$7.0M
Interdisciplinary Infrastructure for Aging Research: Rochester Epidemiology ProjectR33AG058738 · NIA · MAYO CLINIC ROCHESTER · PI LEBRASSEUR, NATHAN K, OLSON, JANET E · 2020 to 2022
$2.4M
NCATS NIH HHS UL1 TR002377NIAMS NIH HHS T32 AR056950NIA NIH HHS R01 AG034676NIA NIH HHS R33 AG058738
6 · The paper itself

Abstract

objectiveTo examine demographic and clinical characteristics associated with diagnostic delay in psoriatic arthritis (PsA).

methodsWe characterized a retrospective, population-based cohort of incident adult (≥ 18 yrs) patients with PsA from Olmsted County, Minnesota, from 2000-2017. All patients met the classification criteria. Diagnostic delay was defined as the time from any patient-reported PsA-related joint symptom to a physician diagnosis of PsA. Factors associated with delay in PsA diagnosis were identified through logistic regression models.

resultsOf the 164 incident PsA cases from 2000 to 2017, 162 had a physician or rheumatologist diagnosis. Mean (SD) age was 41.5 (12.6) years and 46% were female. Median time from symptom onset to physician diagnosis was 2.5 years (IQR 0.5-7.3). By 6 months, 38 (23%) received a diagnosis of PsA, 56 (35%) by 1 year, and 73 (45%) by 2 years after symptom onset. No significant trend in diagnostic delay was observed over calendar time. Earlier age at onset of PsA symptoms, higher BMI, and enthesitis were associated with a diagnostic delay of > 2 years, whereas sebopsoriasis was associated with a lower likelihood of delay.

conclusionIn our study, more than half of PsA patients had a diagnostic delay of > 2 years, and no significant improvement in time to diagnosis was noted between 2000 and 2017. Patients with younger age at PsA symptom onset, higher BMI, or enthesitis before diagnosis were more likely to have a diagnostic delay of > 2 years, whereas patients with sebopsoriasis were less likely to have a diagnostic delay.

Indexed as

Arthritis, PsoriaticDelayed DiagnosisAdultCohort StudiesFemaleHumansRetrospective StudiesRheumatologistsdelaydiagnosispsoriatic arthritisspondyloarthritis

Identifiers

PMID33589556
PMCPMC8364557
OpenAlexW3130834559

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.